Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 6
2014 6
2015 3
2016 4
2017 6
2018 3
2019 7
2020 18
2021 13
2022 8
2023 5
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. Among authors: toyozawa r. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: toyozawa r. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Okahisa M, Udagawa H, Matsumoto S, Kato T, Yokouchi H, Furuya N, Kanemaru R, Toyozawa R, Nishiyama A, Ohashi K, Miyamoto S, Nishino K, Nakamura A, Iwama E, Niho S, Oi H, Sakai T, Shibata Y, Izumi H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Kah Mun Low G, Zhuo J, Goto K. Okahisa M, et al. Among authors: toyozawa r. Lung Cancer. 2024 May;191:107798. doi: 10.1016/j.lungcan.2024.107798. Epub 2024 Apr 23. Lung Cancer. 2024. PMID: 38669727
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).
Tachihara M, Hata A, Tokito T, Hara S, Okada H, Miura S, Sato Y, Tabata E, Watanabe H, Takayama Y, Toyozawa R, Ota K, Wakuda K, Nakamura A, Shimokawa M, Yamamoto N, Nakagawa K. Tachihara M, et al. Among authors: toyozawa r. JTO Clin Res Rep. 2023 Aug 23;4(10):100569. doi: 10.1016/j.jtocrr.2023.100569. eCollection 2023 Oct. JTO Clin Res Rep. 2023. PMID: 37822699 Free PMC article.
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
Takamori S, Matsubara T, Haratake N, Toyokawa G, Fujishita T, Toyozawa R, Ito K, Yamaguchi M, Taguchi K, Okamoto T, Seto T. Takamori S, et al. Among authors: toyozawa r. Front Oncol. 2021 Aug 23;11:704084. doi: 10.3389/fonc.2021.704084. eCollection 2021. Front Oncol. 2021. PMID: 34497761 Free PMC article. Review.
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K. Nosaki K, et al. Among authors: toyozawa r. Int J Clin Oncol. 2024 Aug;29(8):1142-1151. doi: 10.1007/s10147-024-02543-x. Epub 2024 May 17. Int J Clin Oncol. 2024. PMID: 38758397 Clinical Trial.
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Umemura S, et al. Among authors: toyozawa r. J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378-5. doi: 10.1016/j.jtho.2024.10.004. Online ahead of print. J Thorac Oncol. 2024. PMID: 39395663
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.
Niho S, Goto Y, Toyozawa R, Daga H, Ohashi K, Takahashi T, Tanaka H, Sakakibara-Konishi J, Hattori Y, Morise M, Kodani M, Ikeda T, Izumi H, Matsumoto S, Yoh K, Nomura S, Goto K. Niho S, et al. Among authors: toyozawa r. ESMO Open. 2024 Aug;9(8):103642. doi: 10.1016/j.esmoop.2024.103642. Epub 2024 Jul 16. ESMO Open. 2024. PMID: 39018589 Free PMC article. Clinical Trial.
74 results